IL-12p40/IL-23p40 Blockade With Ustekinumab Decreases the Synovial Inflammatory Infiltrate Through Modulation of Multiple Signaling Pathways Including MAPK-ERK and Wnt

mTOR Blockade by Rapamycin in Spondyloarthritis: Impact on Inflammation and New Bone Formation in vitro and in vivo

(2020) Sijia Chen et al.   Frontiers in Immunology

Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis

(2020) Andreas Kerschbaumer et al.   ANNALS OF THE RHEUMATIC DISEASES

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial

(2020) Philip J Mease et al.   LANCET

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial

(2020) Atul Deodhar et al.   LANCET

Selective targeting of PI3Kδ suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseases

(2020) Sijia Chen et al.   JOURNAL OF AUTOIMMUNITY

NOV/CCN3 induces cartilage protection by inhibiting PI3K/AKT/mTOR pathway

(2019) Xiaojian Huang et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Interleukin-7 protects against bacterial respiratory infection by promoting IL-17A-producing innate T-cell response

(2019) Maya Hassane et al.   Mucosal Immunology

IL-17 blockade with secukinumab in peripheral spondyloarthritis impacts synovial immunopathology without compromising systemic immune responses

(2018) Leonieke J. J. van Mens et al.   Arthritis & Rheumatology

The Initiation, but Not the Persistence, of Experimental Spondyloarthritis Is Dependent on Interleukin-23 Signaling

(2018) Melissa N. van Tok et al.   Frontiers in Immunology

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

(2018) Dominique Baeten et al.   ANNALS OF THE RHEUMATIC DISEASES

Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis

(2018) Atul Deodhar et al.   Arthritis & Rheumatology

Tapering and Discontinuation of Biologics in Patients with Psoriatic Arthritis with Low Disease Activity

(2018) Weiyu Ye et al.   DRUGS

Psoriatic skin molecular and histopathological profiles following treatment with risankizumab versus ustekinumab

(2018) Sudha Visvanathan et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Activation of AZIN1 RNA editing is a novel mechanism that promotes invasive potential of cancer-associated fibroblasts in colorectal cancer

(2018) Sho Takeda et al.   CANCER LETTERS

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease

(2016) Stephan R Targan et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)

(2016) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis

(2016) Eric Gracey et al.   ANNALS OF THE RHEUMATIC DISEASES

Dynamic Contrast-Enhanced Magnetic Resonance Imaging Using Pharmacokinetic Modeling: Initial Experience in Patients With Early Arthritis

(2016) Karen I. Maijer et al.   Arthritis & Rheumatology

CD11c+ monocyte/macrophages promote chronic Helicobacter hepaticus-induced intestinal inflammation through the production of IL-23

(2015) I C Arnold et al.   Mucosal Immunology

Targeted mutation of NOV/CCN3 in mice disrupts joint homeostasis and causes osteoarthritis-like disease

(2015) K.A. Roddy et al.   OSTEOARTHRITIS AND CARTILAGE

Immunopathology of synovitis: from histology to molecular pathways

(2015) Marleen G. van de Sande et al.   RHEUMATOLOGY

Gene Expression Profiling in Peripheral Blood Cells and Synovial Membranes of Patients with Psoriatic Arthritis

(2015) Marzia Dolcino et al.   PLoS One

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

(2014) Christopher Ritchlin et al.   ANNALS OF THE RHEUMATIC DISEASES

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

(2014) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Role of PI3K/Akt and mTOR complexes in Th17 cell differentiation

(2013) Shigenori Nagai et al.   Annals of the New York Academy of Sciences

High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission

(2013) Elizabeth G Araujo et al.   ANNALS OF THE RHEUMATIC DISEASES

Peripheral joint inflammation in early onset spondyloarthritis is not specifically related to enthesitis

(2013) Jacqueline E Paramarta et al.   ANNALS OF THE RHEUMATIC DISEASES

Polyamines and Their Metabolites as Diagnostic Markers of Human Diseases

(2013) Myung Hee Park et al.   Biomolecules & Therapeutics

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

(2013) Iain B McInnes et al.   LANCET

Deficiency for the ER-stress transducer OASIS causes severe recessive osteogenesis imperfecta in humans

(2013) Sofie Symoens et al.   Orphanet Journal of Rare Diseases

Langerinneg conventional dendritic cells produce IL-23 to drive psoriatic plaque formation in mice

(2013) C. Wohn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Disease-specific and inflammation-independent stromal alterations in spondylarthritis synovitis

(2012) Nataliya Yeremenko et al.   ARTHRITIS AND RHEUMATISM

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

(2012) Wolfgang Hueber et al.   GUT

Blockade of Phosphatidylinositol 3-Kinase (PI3K)δ or PI3Kγ Reduces IL-17 and Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis

(2012) Anne Roller et al.   JOURNAL OF IMMUNOLOGY

IL-12 family cytokines: immunological playmakers

(2012) Dario A A Vignali et al.   NATURE IMMUNOLOGY

MUC1 enhances hypoxia-driven angiogenesis through the regulation of multiple proangiogenic factors

(2012) S Kitamoto et al.   ONCOGENE

Selective involvement of ERK and JNK mitogen-activated protein kinases in early rheumatoid arthritis (1987 ACR criteria compared to 2010 ACR/EULAR criteria): a prospective study aimed at identification of diagnostic and prognostic biomarkers as well as therapeutic targets

(2011) Daphne de Launay et al.   ANNALS OF THE RHEUMATIC DISEASES

Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials

(2010) M. G. H. van de Sande et al.   ANNALS OF THE RHEUMATIC DISEASES

edgeR: a Bioconductor package for differential expression analysis of digital gene expression data

(2009) M. D. Robinson et al.   BIOINFORMATICS

Signalling mediated by the endoplasmic reticulum stress transducer OASIS is involved in bone formation

(2009) Tomohiko Murakami et al.   NATURE CELL BIOLOGY

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

(2009) Da Wei Huang et al.   Nature Protocols

A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue

(2008) A W R van Kuijk et al.   ANNALS OF THE RHEUMATIC DISEASES

Genetic Variants of the IL-23R Pathway: Association with Psoriatic Arthritis and Psoriasis Vulgaris, but No Specific Risk Factor for Arthritis

(2008) Ulrike Hüffmeier et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY